BriaCell Therapeutics Corp. shares fluctuated on Monday after the company reported a key milestone in its Bria-MEL+ melanoma vaccine program, initially surging 25% before paring gains.
The advance follows a genetic engineering breakthrough that moves the cell-based therapeutic cancer vaccine closer to clinical development. Bria-MEL+ is designed as a personalized yet off-the-shelf treatment, leveraging a patient saliva test to select from premanufactured cell lines, thereby avoiding individualized manufacturing for each patient.
BriaCell, headquartered in Philadelphia and Vancouver, cited U.S. projections estimating approximately 112,000 new melanoma cases and 8,510 deaths in 2026. The company’s broader platform, previously focused on metastatic breast cancer immunotherapy, is expanding into melanoma and prostate cancer treatments.
William V. Williams, President and Chief Executive Officer of BriaCell, stated that Bria-MEL+ aims to combine the benefits of personalized immunotherapy with the accessibility of an off-the-shelf vaccine. The approach is intended to broaden patient access, shorten treatment timelines, and reduce costs while maintaining patient-specific matching.
